Domača stranTMOS34 • BVMF
add
Thermo Fisher Scientific
Prejšnji trg. dan.
52,00 R$
Dnevni razpon
52,00 R$ - 53,89 R$
Letni razpon
44,30 R$ - 74,45 R$
Tržna kapitalizacija
181,05 mrd. USD
Povprečni obseg
20,74 tis.
Razm. P/E
-
Dividendna donosnost
-
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 10,86 mrd. | 2,98 % |
Stroški poslovanja | 2,48 mrd. | −1,47 % |
Čisti dohodek | 1,62 mrd. | 4,46 % |
Čista dobičkovnost prihodkov | 14,90 | 1,43 % |
Earnings per share | 5,36 | −0,19 % |
EBITDA | 2,62 mrd. | −0,04 % |
Efektivna davčna stopnja | 5,38 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 6,39 mrd. | −27,58 % |
Skupna sredstva | 101,23 mrd. | 2,78 % |
Skupne obveznosti | 50,63 mrd. | −0,66 % |
Celoten lastniški kapital | 50,60 mrd. | — |
Shares outstanding | 377,61 mio. | — |
Razmerje P/B | 0,39 | — |
Donosnost sredstev | 4,84 % | — |
Donosnost kapitala | 5,71 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 1,62 mrd. | 4,46 % |
Denar iz dejavnosti | 1,40 mrd. | −28,62 % |
Denar iz naložb | −288,00 mio. | −13,83 % |
Denar iz financiranja | −991,00 mio. | −761,74 % |
Neto sprememba denarnih sredstev | 431,00 mio. | −72,69 % |
Prost denarni tok | 736,12 mio. | −44,08 % |
Vizitka
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain. Wikipedia
Generalni direktor
Datum ustanovitve
1956
Sedež organizacije
Spletno mesto
Zaposleni
125.000
